|
|
|
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) |
|
Oramed Pharmaceuticals Inc
ORMP's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Oramed Pharmaceuticals Inc's sales fell
in the fourth quarter of 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.85 %
Oramed Pharmaceuticals Inc faced net loss in contrast to the net income a year ago in fourth quarter of 2024
• More on ORMP's Growth
|
|
Oramed Pharmaceuticals Inc
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.88 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.2.
• More on ORMP's Valuation
|
|
|
|
|
Oramed Pharmaceuticals Inc
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.88 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.2.
Oramed Pharmaceuticals Inc Price to Book Ratio is at 0.59 lower than Industry Avg. of 33.32. and higher than S&P 500 Avg. of 0.01
• More on ORMP's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
